Results 101 to 110 of about 2,513,768 (223)

Lymphatic transport of bile acids in man

open access: yesJournal of Lipid Research, 1982
The possibility of a lymphatic transport of bile acids in man was investigated. Four patients were studied 2-4 weeks after renal transplantation.
S Ewerth   +3 more
doaj   +1 more source

High-concentrate diet decreases lamb fatty acid contents by regulating bile acid composition

open access: yesFood Chemistry: X
Feeding sheep with high-concentrate diet (HCD) to shorten production cycle is a well-developed feeding strategy to increase lamb production. Here, metabolomics were performed to explore the mechanism that HCD changes lamb nutrition composition ...
Kaizhi Zheng   +10 more
doaj   +1 more source

Chenodeoxycholic acid stimulated fibroblast growth factor 19 response:a potential biochemical test for bile acid diarrhoea

open access: yes, 2017
BACKGROUND: Bile acid diarrhoea is underdiagnosed and better diagnostic tests are needed. Fasting serum fibroblast growth factor-19 (FGF19) has insufficient diagnostic value, but this may be improved by stimulation.AIM: To explore if an impaired FGF19 ...
Borup, C   +17 more
core   +1 more source

Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine ß-cell Survival and the Inflammatory Response

open access: yes, 2016
In past studies using hydrogel-polyelectrolyte matrix and different bile acid excipients, we microencapsulated pancreatic ß-cells using various methods, and the microcapsules were mechanically stable, displayed good morphological characteristics with ...
Negrulj, R.   +2 more
core   +2 more sources

Effects of bile acid depletion and of ursodeoxycholic and chenodeoxycholic acids on biliary protein secretion in the hamster

open access: yes, 1990
The effect of changes of both the rate of secretion and the composition of bile acids on biliary proteins was studied in a bile fistula hamster model.
Shehan, Kathleen L.   +3 more
core   +1 more source

Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group

open access: yes, 2001
Combination therapy using ursodeoxycholic acid plus chenodeoxycholic acid has been advocated for dissolution of cholesterol gallstones because the two bile acids have complementary effects on biliary lipid metabolism and cholesterol ...
M. Fracchia   +11 more
core   +1 more source

Competition in liver transport between chenodeoxycholic acid and ursodeoxycholic acid as a mechanism for ursodeoxycholic acid and its amidates' protection of liver damage induced by chenodeoxycholic acid

open access: yes, 1999
Background. Ursodeoxycholic acid has been widely used as a therapeutic agent in cholesterol gallstones and liver disease patients, but its mechanism of action is still under investigation. Aims.
Montagnani M.   +6 more
core   +1 more source

Relationship between the serum bile acid or chenodeoxycholic acid concentration with bioavailability (A,B), propranolol AUC after oral application (C,D), and clearance after intravenous application (E,F).

open access: yes, 2014
Relationship between the serum bile acid or chenodeoxycholic acid concentration with bioavailability (A,B), propranolol AUC after oral application (C,D), and clearance after intravenous application (E,F).
Jürgen Drewe (573825)   +7 more
core   +1 more source

Isolation and identification of Δ6-lithocholenic acid (3α-hydroxy-5β-6-cholen-24-oic acid) as an intestinal bacterial metabolite of chenodeoxycholic acid in man

open access: yes, 1985
Fecal bacterial biotransformation studies of chenodeoxycholic acid were performed. Incubations were carried out for 30-s to 12-h time intervals. Δ6-Lithocholenic acid was isolated by thin-layer chromatography.
Malavolti, M.   +3 more
core  

INT-767 reduces cholic acid and its metabolites but not chenodeoxycholic acid though the reduction of hepatic CYP7A1 and CYP8B1 expression in ApoE−/− mice.

open access: yes, 2014
A) mRNA levels of hepatic FXR targets in ApoE−/− mice treated with INT-767. B) Serum bile acid content in ApoE−/− mice treated with INT-767.
Audrey L. Keenan (631792)   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy